CHICAGO / Dec 18, 2023 / Business Wire / GE HealthCare (Nasdaq: GEHC) is announcing today that President and Chief Executive Officer, Peter Arduini, and Vice President and Chief Financial Officer, Jay Saccaro, will attend the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th in San Francisco. Both GE HealthCare executives will participate in a Q&A session following Arduini’s presentation at 2:15 pm ET/11:15 am PT.
This live webcast can be accessed by visiting GE HealthCare’s Investor Relations website here https://investor.gehealthcare.com/news-events/events, where it will also be archived.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are an $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on LinkedIn, Twitter, and Insights for the latest news, or visit our website gehealthcare.com for more information.
| Last Trade: | US$62.37 |
| Daily Change: | 0.89 1.45 |
| Daily Volume: | 4,161,841 |
| Market Cap: | US$28.490B |
April 10, 2025 March 31, 2025 March 28, 2025 March 27, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
